Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Autor: Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, Rochelle Bailey, Jianhua Zhong, C. L. Beach, Herve Dombret

Publikováno v: Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-14 (2021)

Abstract Background Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacit

Externí odkaz: https://doaj.org/article/643e4039c05b4d0693acd3685dcccc4b

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Autor: Joaquin Martinez-Lopez, Laida Cuevas Palomares, Pilar Rodríguez Martínez, María Belén Vidriales Vicente, Susana Vives, Raimundo Garcia Boyero, Isabel Cano, Lourdes Hermosín Ramos, María Carmen Mateos Rodríguez, Cristian Escolano Escobar, María Telesa Olave, Cristina Seri Merino, Montserrat Arnan Sangerman, Juan Miguel Bergua Burgues, Marta Cervera Calvo, María Elena Amutio Diez, Javier Cornago Navascués, Jose Luis Lopez Lorenzo, Miguel A. Sanz, Carmen Botella Prieto, José Luis Piñana, Josefina Serrano, Almudena de Laiglesiai, Jesús Lorenzo Algarra, Alejandro Contento Gonzalo, Pau Montesinos, Carlos Cerveró, Pilar Herrera, Rebeca Cuello García, Gabriela Rodriguez Macias, Marta Sobas, Angela Figuera Alvarez, Begona Navas Elorza, María Josefa Najera Irazu, Maria Angeles Foncillas, Dunia De Miguel Llorente, Erik de Cabo López, Alicia Roldán Pérez, Teresa Bernal del Castillo, Juan Eduardo Megías-Vericat, Paola Sandra Villafuerte Gutierrez, Villegas A, Tomás Palanques-Pastor

Publikováno v: Leukemia & lymphoma
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
LEUKEMIA & LYMPHOMA
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2213676a4f3ebf8d1e2cd0a70b6679f
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=14915

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Autor: Erik de Cabo López, María Teresa Olave, Alicia Roldán Pérez, Teresa Bernal del Castillo, Miguel A. Sanz, Pilar Rodríguez Martínez, Jesús Lorenzo Algarra, Josefina Serrano, Susana Vives, María Carmen Mateos Rodríguez, María-Belén Vidriales, Cristina Seri, Isabel Cano, Cristian Escolano Escobar, Marta Cervera, Pau Montesinos, Angela Figuera Alvarez, Jose Luiz Lopez Lorenzo, Jose Luis Piñana Sanchez, Maria Angeles Foncillas, Juan Miguel Bergua Burgues, Carlos Cerveró, Montserrat Arnan Sangerman, Laida Cuevas Palomares, Marta Sobas, Javier Cornago Navascués, Almudena de Laiglesia, Paola Sandra Villafuerte Gutierrez, Villegas A, Maria Dunia De Miguel, Pilar Herrera Puente, María Josefa Najera Irazu, Carmen Botella, Maria Lourdes Hermosin, María Elena Amutio Diez, Gabriela Rodríguez-Macías, Joaquin Martinez-Lopez, Tomás Palanques Pastor, Begoña Navas, Alejandro Contento-Gonzalo, Rebeca Cuello, Raimundo García-Boyero

Publikováno v: Blood

SARS-CoV-2 infection can impact survival of patients with acute myeloid leukemia (AML). International experts recommend considering delaying or stopping AML treatment, test patients who need intensive induction and s prioritizing outpatient treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70f23c09142168134744d56888968f8c
http://europepmc.org/articles/PMC8330287